- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Rhelion Life Sciences Corp: Rhelion unit expands PEX010 supply for Italian trial | 6 | Stockwatch | ||
| Fr | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy | 352 | Newsfile | Following authorization of the TEMPO trial under the European Union Clinical Trials Regulation, Filament has expanded its supply agreement with the University G. d'Annunzio of Chieti-Pescara to support... ► Artikel lesen | |
| Di | Rhelion Life Sciences Corp: Rhelion unit Filament receives Canadian patent | 4 | Stockwatch | ||
| Di | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate | 392 | Newsfile | A new Canadian patent, "Psychoactive Alkaloid Extraction and Composition with Controlled Dephosphorylation," has been issued by the Canadian Intellectual Property Office, adding to the intellectual... ► Artikel lesen | |
| Mo | Rhelion Life Sciences Corp: Rhelion's Filament Health ships PEX010 to Bruyere | 4 | Stockwatch | ||
| Mo | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care | 323 | Newsfile | Filament has shipped PEX010 to Bruyère Health Research Institute for its Phase 3 placebo-controlled trial, which follows a published Phase I/II study that found microdose psilocybin safe, feasible and... ► Artikel lesen | |
| 17.09. | Rhelion Life Sciences Corp: Rhelion Life unit to supply PEX010 for Dutch study | 2 | Stockwatch | ||
| RHELION LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 17.09. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin | 269 | Newsfile | Filament will supply PEX010 1 mg and 5 mg capsules, with matching placebo, for a study of low and medium dose psilocybin sponsored by the Centre for Human Drug Research in Leiden, the Netherlands.Toronto... ► Artikel lesen | |
| 16.09. | Rhelion Life Sciences Corp: Rhelion enters supply deal with University of S. Calif. | 7 | Stockwatch | ||
| 15.09. | Rhelion Life Sciences Corp.: Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy | 220 | Newsfile | Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation... ► Artikel lesen | |
| 14.09. | Rhelion Life Sciences Corp: Rhelion unit to speak at FDA psychedelics hearing | 8 | Stockwatch | ||
| 14.09. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs | 360 | Newsfile | Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of... ► Artikel lesen | |
| 11.09. | Rhelion Life Sciences Corp: Rhelion's Filament plans stability program for IBEX011 | 7 | Stockwatch | ||
| 10.09. | Rhelion Life Sciences Corp.: Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate | 281 | Newsfile | Filament Health has begun planning a stability program for IBEX011, its naturally derived botanical ibogaine drug candidate, in response to growing demand for GMP quality, standardized ibogaine for... ► Artikel lesen | |
| 09.09. | Rhelion Life Sciences Corp: Rhelion ships PEX010 to Australia for FND trial | 3 | Stockwatch | ||
| 08.09. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder | 311 | Newsfile | Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted... ► Artikel lesen | |
| 31.08. | Red Light Holland reports Q1 results | 4 | Seeking Alpha | ||
| 28.08. | Rhelion Life Sciences Corp: Rhelion's Filament gains new U.S. psilocybin patent | 11 | Stockwatch | ||
| 27.08. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate | 910 | Newsfile | A new United States patent, "Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids," issued this month, adding to the intellectual property estate behind PEX010, the... ► Artikel lesen | |
| 25.08. | Rhelion Life Sciences Corp: Rhelion subsidiary ships psilocybin for cancer trial | 6 | Stockwatch |
1 2 3 4 5 Weiter >>
89 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 50,02 | +1,30 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| NOVO NORDISK | 33,890 | +0,62 % | Novo Nordisk Showdown: Montag muss das Management liefern | Die Novo-Nordisk-Aktie steht vor einem wichtigen Termin. Am Montag, 21. September, legt der Pharmakonzern in London seine aktualisierte Strategie und die mittelfristigen Ziele vor. Nach einem deutlichen... ► Artikel lesen | |
| NOVARTIS | 127,10 | -0,14 % | GOLDMAN SACHS stuft NOVARTIS AG auf 'Sell' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Novartis von 113 auf 110 Franken gesenkt und die Einstufung auf "Sell" belassen. Das aktuelle Bewertungsniveau... ► Artikel lesen | |
| AURORA CANNABIS | 3,586 | -0,17 % | Aurora Cannabis Inc.: Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure | NASDAQ | TSX: ACB
Aurora has filed an application with the Alberta Securities Commission for an order requiring Curaleaf to comply with securities laws.
Aurora intends to demonstrate... ► Artikel lesen | |
| SANOFI | 71,89 | +0,01 % | Sanofi baut Forschung um - was Anleger wissen müssen | ||
| GSK | 21,520 | -1,37 % | Novo Nordisk investiert weitere 1,4 Milliarden Dollar in Biotech: Weshalb Big Pharma immer früher nach dem nächsten Milliardenmarkt sucht | ||
| ELI LILLY | 1.038,60 | -0,04 % | Lilly, Adobe, SoftBank und SpaceX im Wochenrückblick | Es war eine Woche, in der Politik und Technologie ungewöhnlich eng ineinandergriffen. Der Ruf nach einem langsameren KI-Entwicklungstempo traf auf einen geopolitischen Wettlauf, der genau das Gegenteil... ► Artikel lesen | |
| CANOPY GROWTH | 0,821 | +0,81 % | Canopy Growth Corp (2): Canopy Growth adjourns meeting for lack of quorum | ||
| STADA ARZNEIMITTEL | - | - | Nahrungsergänzungsmittel: Stada bringt Eunova Menopause | ||
| TILRAY BRANDS | 3,625 | -0,14 % | Tilray Brands, Inc.: BrewDog Launches 'Under New Ownership' Campaign, Marking a New Era of Fresh Energy, New Backing and Award-Winning Beer | Under Tilray ownership, BrewDog is back on the front foot - with fresh investment, renewed energy and award-winning beers driving the next chapter for one of the UK and Europe's biggest craft beer brands.
ELLON... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 35,000 | +4,17 % | Teva Pharmaceutical Industries Ltd: Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET | TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 460,00 | -0,39 % | Vertex Pharmaceuticals Incorporated: Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial | In people with AMKD with modest proteinuria, treatment with inaxaplin led to a reduction in urine albumin to creatinine ratio (UACR) of -42.7% at Week 13 compared to baseline - - In people with... ► Artikel lesen | |
| ABBOTT LABORATORIES | 88,88 | 0,00 % | Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery | ||
| INNOCAN PHARMA | 1,225 | +2,51 % | Innocan Pharma Corporation: Innocan Pharma Announces First Tranche Closing of Private Placement of Units | HERZLIYA, Israel and CALGARY, Alberta, Sept. 23, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that, further... ► Artikel lesen | |
| MPH HEALTH CARE | 26,300 | +0,77 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
21.09.2026 / 13:15 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen |
Das Unternehmen RHELION LIFE SCIENCES CORP kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,009 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RHELION LIFE SCIENCES CORP finden Sie auf Wallstreet Online.